Symbiotec Pharmalab
Pharmaceutical maker of active ingredients, CDMO services and complex injectables.
Last updated 9 Sept 2026, 10:59 am IST
- Price band
- ₹938 – ₹988
- Lot size
- 15
- Issue size
- ₹1,757 Cr
- Opens
- 24 Aug 2026
- Closes
- 27 Aug 2026
- Exchange
- Both
The numbers
- GMP
- ₹260 (~26.3%) (listing eve; was ₹282 (~28.5%))
- Subscription
- 75.08× (final)
- Listing gain
- NSE 0.0% / BSE -1.0% (1 Sep)
- Listing date
- 1 Sept 2026
- Model prediction
- ~+34% expected → Strong Subscribe. Listed flat on NSE / -1.0% BSE (1 Sep), closed +11.1%; read ran high.
The Ticker Tales take
Symbiotec Pharmalab develops and makes active pharmaceutical ingredients, offers contract development and manufacturing (CDMO), and makes complex injectables. ₹1,757 Cr mainboard issue at ₹938–988 that closed on 27 Aug. After a slow start the big money came in late and demand finished at ~75.08× (institutions ~181×, wealthy investors ~77.6×, retail ~13.7×), while the grey-market premium eased to ~₹260 (~26% over ₹988). Anil Singhvi posted a review video but no clear verdict. Our locked call was Strong Subscribe on an expected pop of roughly 34%. It listed on 1 Sep exactly at the ₹988 issue price on NSE (₹978 on BSE, −1.0%) — no pop at all — then recovered through the day to close at ₹1,097.70 (+11.1%). Applicants who held through day one made money, but our number was well over the mark.
More details
- Anil Singhvi - Long-term call
- Not clearly stated
- Anil Singhvi - Listing-gain call
- Not clearly stated
Want a heads-up when a new IPO opens?
We'll email you when one opens — and only then.
No spam, ever. Leave whenever you like.
Calls here follow a set formula (GMP, subscription trends) plus Anil Singhvi's publicly shared view — not investment advice. Please do your own research before investing.